Article

Surya Singh, MD, Addresses Ways to Manage Oncology Spending in Specialty Pharmacy

Dr. Singh discusses CVS Caremark's strategies for managing oncology spending.

Surya Singh, MD, Vice President, Medical Benefit Management, CVS Caremark, states that there are a variety of approaches used to stem the rise of costs associated with oncology. However, Dr. Singh point out that there is not a one-size-fits-all approach to doing so.

Related Videos
Mei Wei, MD.
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Sandra Cueller, PharmD
Ticiana Leal, MD
James Chambers, PhD
Mabel Mardones, MD.
Dr Bonnie Qin
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Related Content
Don M. Benson, MD, PhD, James Cancer Hospital
November 22nd 2024

Balancing Life and Myeloma: A Patient-Centered Approach

Maggie L. Shaw
In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Managed Care Cast
November 21st 2024

Frameworks for Advancing Health Equity: Wellness Way

Giuliana Grossi
The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.
Martin Dietrich, MD, PhD
November 21st 2024

Research Priorities Evolve With Amivantamab's Broader NSCLC Indications

Maggie L. Shaw
In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC).
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
Non-Hodgkin Lymphoma | Image Credit: © MQ-Illustrations - stock.adobe.com
November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser
Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).
Latest From FINEARTS-HF: No Sex-Specific Differences in Finerenone Outcomes for Heart Failure
November 18th 2024

Latest From FINEARTS-HF: No Sex-Specific Differences in Finerenone Outcomes for Heart Failure

Kyle Munz
The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo